| Code: | AC-10F1 |
|---|---|
| Certification: |
FDA Cleared |
| Clinical Area: | Cartilage Markers |
| Type: | Manual |
| Format: | EIA |
| RUO/IVD: | IVD |
| Number of Tests: | 96 (40 samples in duplicate) |
| Sample Type: | Urine |
| Sample Volume: | 40 µL |
| Assay Range: | 0-10 ng/mL |
Unique Features
- Quantitative assessment of disease activity (structural damage of articular cartilage) in patients with RA and OA
- Prognosis of disease activity in patients with RA and OA
- Early assessment of long-term effect of therapy in patients with RA
- Excellent correlation to immunohistochemistry and imaging techniques
- A complete assay panel supporting clinical bone and cartilage research
The Urine CartiLaps® (CTX-II) EIA detects degradation products of C-terminal telopeptides of type II collagen.
It is intended for in-vitro diagnostic use as an indication of degradation of cartilage and may be used as an aid for:
- Quantitative assessment of disease activity (structural damage of articular cartilage) in patients with RA and OA.
- Prognosis of disease activity in patients with RA and OA, and early assessment of long-term effect of therapy in patients with RA.
Disruption of the structural integrity of cartilage is the major histological finding in osteoarthritis and rheumatoid arthritis. Type II collagen is the major organic constituent of cartilage. Fragments of type II collagen (CTX-II) are being released into circulation and subsequently secreted into urine following degradation of cartilage.
In urine, the CTX-II fragments can be quantified by Urine CartiLaps® (CTX-II) EIA. The Urine CartiLaps® (CTX-II) EIA has been reported to be useful in prediction of the progression of osteoarthritis (Reijman et al.2, Garnero et al1), and in other clinical (Rotterud3) and pre-clinical investigations.
Garnero P. et al., Cross-sectional association of 10 molecular markers of bone, cartilage, and synovium with disease activity and radiological joint damage in patients with hip osteoarthritis: the ECHODIAH cohort.
Reijman M et al., A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum. 2004 Aug;50(8):2471-8.
Rotterud JH et al., Relationship between CTX-II and patient characteristics, patient-reported outcome, muscle strength, and rehabilitation in patients with a focal cartilage lesion of the knee: a prospective exploratory cohort study of 48 patients. BMC Musculoskelet Disord. 2014 Mar 24;15:99.
COMP ELISA
Bone Markers
